0001556244-19-000061.txt : 20190701 0001556244-19-000061.hdr.sgml : 20190701 20190701152327 ACCESSION NUMBER: 0001556244-19-000061 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190701 DATE AS OF CHANGE: 20190701 EFFECTIVENESS DATE: 20190701 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AdvanSource Biomaterials Corp CENTRAL INDEX KEY: 0001011060 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043186647 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11737 FILM NUMBER: 19932966 BUSINESS ADDRESS: STREET 1: 229 ANDOVER STREET CITY: WILMINGTON STATE: MA ZIP: 01887 BUSINESS PHONE: 978-657-0075 MAIL ADDRESS: STREET 1: 229 ANDOVER STREET CITY: WILMINGTON STATE: MA ZIP: 01887 FORMER COMPANY: FORMER CONFORMED NAME: CARDIOTECH INTERNATIONAL INC DATE OF NAME CHANGE: 19960321 NT 10-K 1 asnb190331_nt10k.htm 190701 ASNB FORM 12B-25 FOR 190331 FORM 10-K Form 12b-25 for March 31, 2009 Form 10-Q  (M0077514.DOC;2)


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION


WASHINGTON, D.C. 20549


FORM 12b-25


NOTIFICATION OF LATE FILING


(Check One):


[X] Form 10-K  [ ] Form 20-F  [ ] Form 11-K  [ ] Form 10-Q  [ ] Form 20-D  [ ] Form N-SAR

[ ] Form N-CSR


For Period Ended:  March 31, 2019


[ ] Transition Report on Form 10-K

[ ] Transition Report on Form 20-F

[ ] Transition Report on Form 11-K

[ ] Transition Report on Form 10-Q

[ ] Transition Report on Form N-SAR


For the Transition Period Ended:  N/A


Read Instruction (on back page) Before Preparing Form. Please print or type.


Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:________________________



PART I – REGISTRANT INFORMATION


Full name of registrant:

AdvanSource Biomaterials Corporation


Former name if applicable:

N/A


Address of principal executive office (Street and number):

229 Andover Street


City, State and Zip Code:

Wilmington, Massachusetts  01887





PART II – RULE 12b-25(b) AND (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

[X]

(a)  The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

[X]

(b)  The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and


(c)  The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III – NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed.)

The Registrant was unable, without unreasonable effort and expense, to prepare its accounting records and schedules in sufficient time to enable its independent registered public accounting firm to complete its annual audit of the Registrant’s financial statements to be contained in its Annual Report on Form 10-K for the year ended March 31, 2019 on or before June 29, 2019. The subject annual report on Form 10-K will be filed on or before the fifteenth (15th) calendar day following the prescribed due date of June 29, 2019.

PART IV – OTHER INFORMATION

(1)

Name and telephone number of person to contact in regard to this notification:

Michael F. Adams


978-657-0075

(Name)


(Area Code & Telephone Number)

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).



[X]Yes

[  ]No



(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?



[  ]Yes

[X]No




If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.



AdvanSource Biomaterials Corporation

(Name of registrant as specified in charter)


Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized by the Chairman of the Board of Directors.



By:  /s/  Michael F. Adams

Michael F. Adams

President and Chief Executive Officer

Date:  July 1, 2019





INSTRUCTION.  The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.



ATTENTION


Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).